Journal article Open Access
Rohit Dangi*, Rahul Sharma, Dr. Jagdish Chandra Rathi
In the last decade, interest in developing a combination of two or more Active Pharmaceutical Ingredients (API) in a single dosage form (bi-layer tablet) has increased in the pharmaceutical industry, promoting patient convenience and compliance. The present research work was envisaged to develop bilayer tablets to improve therapeutic efficacy of anti-HIV/AIDS drugs for the treatment of sexually transmitted diseases. The combination of two anti-HIV/AIDS drugs i.e. abacavir and lamivudine were used for the preparation of bilayer tablets which act HIV/AIDS infections. The formulations comprise of abacavir as immediate release layer formulated using different superdisintegrants and lamivudine as extended-release layer containing HPMC K4, K15. Evaluation of bilayer tablets were performed for the immediate release abacavir layer and sustain release lamivudine layer with optimization of excipients. The immediate release layer of abacavir showed complete release within 90 min and lamivudine release was extended up to 12 hours. The present study revealed that abacavir and lamivudine bilayer tablets were successfully developed for the use against sexually transmitted infections.
Keywords: Bi-layer tablet, Abacavir, Lamivudine, HIV/AIDS, Superdisintegrants, HPMC